Under the agreement, Icon will provide clinical pharmacology and exploratory clinical trial services including study conduct in Icon’s clinical pharmacology units, located in San Antonio, Texas; Omaha, Nebraska; and Manchester, UK.
Icon will also provide all supporting scientific services such as protocol design and development, project management, clinical monitoring, medical monitoring / pharmacovigilence, data management, biostatistics, pharmacokinetics and medical writing.
Icon Development Solutions president Mario Rocci said both companies already have a successful partnership for phase II-IV clinical development and central laboratory services and they look forward to demonstrate the same value and efficiencies to Bristol-Myers-Squibb‘s early phase clinical programs.